Shopping Cart
Remove All
Your shopping cart is currently empty
Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,330 | - | In Stock | |
| 25 mg | $1,980 | - | In Stock | |
| 50 mg | $2,680 | - | In Stock |
| Description | Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease. |
| In vitro | Methods: Visilizumab (1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10,000 ng/mL, 2-48 hours (samples were taken and analyzed at 2, 4, 20, 24, and 48 hours)) was used to treat lamina propria T cells and observe their cell growth. Results: Visilizumab was able to induce dose- and time-dependent apoptosis of lamina propria T cells. [1] |
| Synonyms | HuM291, Anti-Human CD3E Recombinant Antibody |
| Cas No. | 219716-33-3 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.